...
首页> 外文期刊>Modern Pathology >Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma
【24h】

Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma

机译:hMLH1和hMSH2的免疫组织化学染色反映了卵巢癌中微卫星的不稳定性状态

获取原文
           

摘要

Microsatellite instability is due to defects in the family of DNA repair genes, primarily hMLH1 and hMSH2, which can be detected by immunohistochemical staining. However, it is unclear whether immunohistochemical staining can accurately predict microsatellite instability status. We sought here to evaluate the sensitivity, specificity, and predictive values of immunostaining for the expression of the DNA mismatch-repair genes hMLH1 or hMSH2 in predicting microsatellite instability in ovarian carcinoma. Tissue microarrays with specimens from 322 women with primary ovarian carcinoma were stained with antibodies to hMLH1 and hMSH2; cases in which either hMLH1 or hMSH2 were negative were analyzed for microsatellite instability with the five-marker panel recommended by the National Cancer Institute (BAT26, BAT25, D5S346, D2S123, and D17S250). Microsatellite instability was also analyzed in another 19 cases selected at random in which both hMLH1 and hMSH2 were positive. Tumors with instability at two or more of the five NCI markers were considered to have a high level of microsatellite instability; tumors showing instability at only one marker were considered microsatellite instability-low; and tumors in which no markers exhibited microsatellite instability were considered microsatellite stable. We found that negative staining for hMLH1 protein (five cases) or hMSH2 protein (two cases) was associated with high level of microsatellite instability. The sensitivity and specificity of immunohistochemical staining for hMLH1 were 62 and 100% and those of hMSH2 alone were 25 and 100%. Combining loss of expression of both hMLH1 and hMSH2 led to sensitivity, specificity, and positive and negative predictive values of 87, 100, 100, and 95%. These results suggest that use of a two-molecule panel (hMLH1 and hMSH2) can accurately determine the microsatellite instability status of patients with ovarian cancer.
机译:微卫星的不稳定性是由于DNA修复基因家族中的缺陷,主要是hMLH1和hMSH2,可以通过免疫组织化学染色检测到。但是,尚不清楚免疫组织化学染色是否可以准确预测微卫星的不稳定性状态。我们在这里寻求评估DNA错配修复基因hMLH1或hMSH2的表达在卵巢癌微卫星不稳定性预测中的敏感性,特异性和预测价值。用针对hMLH1和hMSH2的抗体对322例原发性卵巢癌女性的组织微阵列进行染色。使用国家癌症研究所推荐的五标记小组(BAT26,BAT25,D5S346,D2S123和D17S250)分析hMLH1或hMSH2阴性的病例的微卫星不稳定性。还随机分析了另外19例hMLH1和hMSH2均为阳性的微卫星不稳定性。在五个NCI标志物中有两个或多个具有不稳定性的肿瘤被认为具有很高的微卫星不稳定性;仅在一种标记上显示不稳定性的肿瘤被认为是微卫星不稳定性低;没有标记物表现出微卫星不稳定性的肿瘤被认为是微卫星稳定的。我们发现hMLH1蛋白(5例)或hMSH2蛋白(2例)的阴性染色与高水平的微卫星不稳定性有关。免疫组化染色对hMLH1的敏感性和特异性分别为62和100 %,而仅hMSH2的敏感性和特异性分别为25和100 %。 hMLH1和hMSH2两者表达的共同丧失导致敏感性,特异性以及阳性预测值和阴性预测值分别为87%,100%,100%和95%。这些结果表明,使用两个分子的面板(hMLH1和hMSH2)可以准确确定卵巢癌患者的微卫星不稳定性状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号